Serum levels of zinc and copper in patients with Parkinson's disease.
Several recent studies have shown decreased copper and increased zinc concentrations in the substantia nigra and increased copper concentrations in the cerebrospinal fluid of Parkinson's disease patients. To elucidate whether changes in serum levels of these trace elements may increase the risk of developing Parkinson's disease (PD), we assessed serum levels of zinc and copper by flame atomic absorption spectrophotometry, and albumin and ceruloplasmin, in 32 (Zn) and 39 PD patients (Cu), respectively, with their spouses as the control group. Serum zinc, albumin, copper and ceruloplasmin levels and the zinc/albumin and copper/ceruloplasmin ratios, did not differ significantly between the two groups and were not influenced by antiparkinsonian therapy in the PD patients. Serum zinc/albumin ratio (r = 0.43), ceruloplasmin (r = -0.36) and copper/ceruloplasmin ratio (r = 0.36) correlated significantly with age, but not with age of onset, duration of the disease, scores of the Unified Parkinson's Disease Rating Scale and Hoehn and Yahr staging in PD patients. These values did not correlate with age in the control group. These results suggest that serum levels of zinc and copper do not play any role as risk factors for PD.
Jiménez-Jiménez
F J
FJ
Department of Neurology, Hospital Universitario San Carlos, Madrid, Spain.
Fernández-Calle
P
P
Martínez-Vanaclocha
M
M
Herrero
E
E
Molina
J A
JA
Vázquez
A
A
Codoceo
R
R
D000368:Aged; D000978:Antiparkinson Agents / Q000494:pharmacology / Q000627:therapeutic use; D002570:Ceruloplasmin / Q000378:metabolism; D003300:Copper / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000097:blood*; D012307:Risk Factors; D012709:Serum Albumin / Q000378:metabolism; D013054:Spectrophotometry, Atomic; D015032:Zinc / Q000097:blood*
D000978:Antiparkinson Agents; D012709:Serum Albumin; D003300:Copper; D002570:Ceruloplasmin; D015032:Zinc